This cohort study examines prescription medication use and out-of-pocket spending among Indigenous and non-Indigenous Australians after a governmental program to reduce prescription drug co-payments.
This cohort study examines prescription medication use and out-of-pocket spending among Indigenous and non-Indigenous Australians after a governmental program to reduce prescription drug co-payments.
This cohort study estimates long-term personal income losses following hospital diagnosis for selected mental and physical disorders, including depression, alcohol use disorder, stroke, and breast cancer.
This cohort study estimates long-term personal income losses following hospital diagnosis for selected mental and physical disorders, including depression, alcohol use disorder, stroke, and breast cancer.
This cohort study quantifies how many contracts became eligible for quality bonuses due to Categorical Adjustment Index (CAI) adjustments and estimates the association between CAI values, adjusted star ratings, and bonus status in Medicare Advantage contracts between 2014 and 2025.
This cohort study quantifies how many contracts became eligible for quality bonuses due to Categorical Adjustment Index (CAI) adjustments and estimates the association between CAI values, adjusted star ratings, and bonus status in Medicare Advantage contracts between 2014 and 2025.
This Viewpoint discusses the importance of patient and physician lawsuits and how the 2025 US Supreme Court decision Medina v Planned Parenthood South Atlantic may impede access to justice.
This Viewpoint discusses the importance of patient and physician lawsuits and how the 2025 US Supreme Court decision Medina v Planned Parenthood South Atlantic may impede access to justice.
This JAMA Forum discusses the opportunities and challenges facing US Food and Drug Administration (FDA) new approval paths for individualized therapies to treat rare genetic diseases.
This JAMA Forum discusses the opportunities and challenges facing US Food and Drug Administration (FDA) new approval paths for individualized therapies to treat rare genetic diseases.